Impel Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 24, 2023
17 Marzo 2023 - 6:00AM
Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage
pharmaceutical company developing transformative therapies for
people suffering from diseases with high unmet medical needs, today
announced it will host a live webcast on Friday, March 24, 2023, at
8:30 a.m. ET to report its fourth quarter and full year 2022
financial results and provide a business update.
To access the live conference call, please
register using the conference link:
https://register.vevent.com/register. A live webcast of the event
will be available on the Investors section of the Impel
Pharmaceuticals website at https://investors.impelpharma.com/. A
replay of the webcast and accompanying slides will be available on
the Impel Pharmaceuticals website following the event.
About Impel Pharmaceuticals
Impel Pharmaceuticals is a commercial-stage pharmaceutical company
developing transformative therapies for people suffering from
diseases with high unmet medical needs. Impel offers treatments
that pair its proprietary POD® technology with
well-established therapeutics. In September 2021, Impel received
U.S. FDA approval for its first product, Trudhesa® nasal spray,
which is approved in the U.S. for the acute treatment of migraine
with or without aura in adults. In addition to Trudhesa, the
Company continues to address patient needs via licensing and
partnerships.
For additional information about Impel, please
visit www.ImpelPharma.com
Contact:
Media Relations:Melyssa
WeibleElixir Health Public RelationsPhone: (1)
386-366-0616Email: mweible@elixirhealthpr.com
Investor RelationsJanhavi MohiteStern Investor
RelationsPhone: 212-362-1200Email: janhavi.mohite@sternir.com
Impel Pharmaceuticals (NASDAQ:IMPL)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Impel Pharmaceuticals (NASDAQ:IMPL)
Gráfica de Acción Histórica
De May 2023 a May 2024